Jazz Pharmaceuticals falls amid sector rotation despite market gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 26 2024
0mins
Should l Buy JAZZ?
Source: SeekingAlpha
Jazz Pharmaceuticals PLC experienced a price decline of 5.02% as it crossed below its 5-day SMA. This movement occurred while the Nasdaq-100 rose by 0.43% and the S&P 500 increased by 0.21%, indicating a divergence in performance.
The decline in Jazz Pharmaceuticals' stock price is attributed to sector rotation, as investors are shifting their focus away from pharmaceutical stocks despite the overall market strength. This suggests that specific sector dynamics are influencing the stock's performance rather than broader market trends.
Investors may need to reassess their positions in Jazz Pharmaceuticals as the stock's recent performance indicates a potential shift in market sentiment towards other sectors, which could impact future trading strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JAZZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JAZZ
Wall Street analysts forecast JAZZ stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 202.560
Low
188.00
Averages
218.92
High
263.00
Current: 202.560
Low
188.00
Averages
218.92
High
263.00
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jazz Pharmaceuticals to Report Q1 2026 Financial Results on May 5
- Earnings Release Schedule: Jazz Pharmaceuticals will report its Q1 2026 financial results on May 5, 2026, after the U.S. market closes, reflecting the company's commitment to transparency in the biopharma sector.
- Webcast Timing: Management will host a webcast at 4:30 p.m. ET to discuss the financial results and provide a business update, ensuring investors receive timely and critical information.
- Registration Recommendation: Participants are advised to register at least 15 minutes prior to the scheduled webcast to ensure a smooth connection, highlighting the company's emphasis on investor communication.
- Replay Availability: A replay of the webcast will be accessible via the Jazz Pharmaceuticals investor website, allowing investors who cannot attend live to catch up on important updates, thereby enhancing engagement between the company and its investors.
See More
Jazz Pharmaceuticals Presents Research at AAN Annual Meeting on Rare Neurological Disorders
- Research Presentation: Jazz Pharmaceuticals will present six abstracts, including one oral presentation, at the 2026 American Academy of Neurology Annual Meeting, underscoring its ongoing commitment to addressing rare neurological disorders, particularly epilepsy and sleep disorders.
- Clinical Data Update: New data evaluating Epidiolex® in patients with Lennox-Gastaut syndrome, Dravet syndrome, and other refractory epilepsies demonstrate the drug's potential in improving patient quality of life, further solidifying Jazz's leadership in the neuroscience field.
- Focus on Patient Needs: The head of Jazz's neuroscience therapeutic area stated that the research will help the company gain deeper insights into the real treatment needs of patients with rare neurological disorders, thereby driving R&D efforts to close persistent gaps in care.
- Future Outlook: By showcasing research at the AAN Annual Meeting, Jazz Pharmaceuticals not only demonstrates its innovative capabilities in neuroscience but also indicates its commitment to meeting unmet patient needs, potentially laying the groundwork for future market growth.
See More
PHARMA MAR - ROCHE AND JAZZ PHARMACEUTICALS COLLABORATE ON PHASE 3 IMFORTE TRIAL
Trial Overview: The PHARMAMAR Phase 3 trial is being conducted to evaluate the efficacy of a new treatment.
Sponsorship: The trial is sponsored by Roche in collaboration with Jazz Pharmaceuticals.
See More
American Nutrition Association Partners with Jazz Pharmaceuticals to Promote Low Sodium Diets
- Joint Initiative: The American Nutrition Association (ANA) collaborates with Jazz Pharmaceuticals to launch an initiative aimed at providing evidence-based nutritional education for patients with narcolepsy or idiopathic hypersomnia, addressing cardiovascular and cardiometabolic risks.
- High Sodium Risks: Research indicates that patients with narcolepsy experience significantly higher rates of cardiovascular and cardiometabolic comorbidities, with excessive sodium intake being a critical modifiable risk factor for hypertension and cardiovascular disease, necessitating increased awareness through education.
- Patient Empowerment: This partnership will provide patients with credible, science-backed resources to understand the benefits and risks of sodium intake, enabling them to gain greater control over their health choices and improve their quality of life.
- Provider Support: Healthcare providers will receive evidence-based resources to facilitate meaningful discussions with patients about sodium reduction as a cornerstone of cardiovascular risk management, ultimately promoting better patient outcomes.
See More
American Nutrition Association Partners with Jazz Pharmaceuticals to Promote Low Sodium Diets
- Collaborative Initiative: The American Nutrition Association (ANA) has partnered with Jazz Pharmaceuticals to launch an initiative aimed at providing evidence-based nutritional education for patients with narcolepsy and idiopathic hypersomnia, emphasizing the importance of proactive sodium management in addressing cardiovascular and cardiometabolic risks.
- Cardiovascular Risks: Research indicates that individuals with narcolepsy experience significantly higher rates of cardiovascular and cardiometabolic comorbidities, with excessive sodium intake linked to hypertension and cardiovascular disease, contributing to approximately 700,000 deaths annually in the U.S., highlighting the urgent need for increased awareness.
- Patient Empowerment: This collaboration will provide patients with credible, science-backed resources to understand the risks and benefits of sodium intake, enabling them to make informed health choices, while healthcare providers will be better equipped to engage in meaningful discussions with patients about sodium reduction.
- Science and Education Integration: ANA's CEO, Corinne Bush, emphasized that nutrition science is a core value, and this partnership with Jazz Pharmaceuticals aims to translate scientific knowledge into actionable guidance for patients, ultimately improving health outcomes for those affected.
See More
Jazz Pharmaceuticals Unveils New Research Insights at AACR Annual Meeting
- New Drug Research Progress: Jazz Pharmaceuticals will present seven research findings at the 2026 American Association for Cancer Research Annual Meeting, including the application of Ziihera® (zanidatamab-hrii) in HER2-positive tumors, demonstrating significant efficacy in treating metastatic biliary tract cancer, thereby reinforcing its leadership in oncology.
- Clinical Trial Data: Data from the NeoZanHER trial will support the use of zanidatamab in early-stage HER2-positive breast cancer patients, which is expected to enhance the drug's clinical application in a broader range of HER2-expressing tumors, increasing the company's competitiveness in the oncology market.
- Innovative Research Initiatives: Jazz will also showcase studies on dordaviprone and JZP898, with the former showing potent cytotoxic effects in small cell lung cancer cell lines, while the latter demonstrates robust tumor microenvironment engagement in mouse models, indicating potential in tumor immunotherapy.
- Strategic Investments and Collaborations: The research findings not only reflect Jazz's ongoing investment in oncology drug development but also highlight the company's close collaboration with multiple partners, aiming to improve treatment options for patients through innovative therapies and further drive growth in the global biopharmaceutical market.
See More
Jazz Pharmaceuticals to Report Q1 2026 Financial Results on May 5
- Earnings Release Schedule: Jazz Pharmaceuticals will report its Q1 2026 financial results on May 5, 2026, after the U.S. market closes, reflecting the company's commitment to transparency in the biopharma sector.
- Webcast Timing: Management will host a webcast at 4:30 p.m. ET to discuss the financial results and provide a business update, ensuring investors receive timely and critical information.
- Registration Recommendation: Participants are advised to register at least 15 minutes prior to the scheduled webcast to ensure a smooth connection, highlighting the company's emphasis on investor communication.
- Replay Availability: A replay of the webcast will be accessible via the Jazz Pharmaceuticals investor website, allowing investors who cannot attend live to catch up on important updates, thereby enhancing engagement between the company and its investors.
See More
Jazz Pharmaceuticals Presents Research at AAN Annual Meeting on Rare Neurological Disorders
- Research Presentation: Jazz Pharmaceuticals will present six abstracts, including one oral presentation, at the 2026 American Academy of Neurology Annual Meeting, underscoring its ongoing commitment to addressing rare neurological disorders, particularly epilepsy and sleep disorders.
- Clinical Data Update: New data evaluating Epidiolex® in patients with Lennox-Gastaut syndrome, Dravet syndrome, and other refractory epilepsies demonstrate the drug's potential in improving patient quality of life, further solidifying Jazz's leadership in the neuroscience field.
- Focus on Patient Needs: The head of Jazz's neuroscience therapeutic area stated that the research will help the company gain deeper insights into the real treatment needs of patients with rare neurological disorders, thereby driving R&D efforts to close persistent gaps in care.
- Future Outlook: By showcasing research at the AAN Annual Meeting, Jazz Pharmaceuticals not only demonstrates its innovative capabilities in neuroscience but also indicates its commitment to meeting unmet patient needs, potentially laying the groundwork for future market growth.
See More
PHARMA MAR - ROCHE AND JAZZ PHARMACEUTICALS COLLABORATE ON PHASE 3 IMFORTE TRIAL
Trial Overview: The PHARMAMAR Phase 3 trial is being conducted to evaluate the efficacy of a new treatment.
Sponsorship: The trial is sponsored by Roche in collaboration with Jazz Pharmaceuticals.
See More
American Nutrition Association Partners with Jazz Pharmaceuticals to Promote Low Sodium Diets
- Joint Initiative: The American Nutrition Association (ANA) collaborates with Jazz Pharmaceuticals to launch an initiative aimed at providing evidence-based nutritional education for patients with narcolepsy or idiopathic hypersomnia, addressing cardiovascular and cardiometabolic risks.
- High Sodium Risks: Research indicates that patients with narcolepsy experience significantly higher rates of cardiovascular and cardiometabolic comorbidities, with excessive sodium intake being a critical modifiable risk factor for hypertension and cardiovascular disease, necessitating increased awareness through education.
- Patient Empowerment: This partnership will provide patients with credible, science-backed resources to understand the benefits and risks of sodium intake, enabling them to gain greater control over their health choices and improve their quality of life.
- Provider Support: Healthcare providers will receive evidence-based resources to facilitate meaningful discussions with patients about sodium reduction as a cornerstone of cardiovascular risk management, ultimately promoting better patient outcomes.
See More
American Nutrition Association Partners with Jazz Pharmaceuticals to Promote Low Sodium Diets
- Collaborative Initiative: The American Nutrition Association (ANA) has partnered with Jazz Pharmaceuticals to launch an initiative aimed at providing evidence-based nutritional education for patients with narcolepsy and idiopathic hypersomnia, emphasizing the importance of proactive sodium management in addressing cardiovascular and cardiometabolic risks.
- Cardiovascular Risks: Research indicates that individuals with narcolepsy experience significantly higher rates of cardiovascular and cardiometabolic comorbidities, with excessive sodium intake linked to hypertension and cardiovascular disease, contributing to approximately 700,000 deaths annually in the U.S., highlighting the urgent need for increased awareness.
- Patient Empowerment: This collaboration will provide patients with credible, science-backed resources to understand the risks and benefits of sodium intake, enabling them to make informed health choices, while healthcare providers will be better equipped to engage in meaningful discussions with patients about sodium reduction.
- Science and Education Integration: ANA's CEO, Corinne Bush, emphasized that nutrition science is a core value, and this partnership with Jazz Pharmaceuticals aims to translate scientific knowledge into actionable guidance for patients, ultimately improving health outcomes for those affected.
See More
Jazz Pharmaceuticals Unveils New Research Insights at AACR Annual Meeting
- New Drug Research Progress: Jazz Pharmaceuticals will present seven research findings at the 2026 American Association for Cancer Research Annual Meeting, including the application of Ziihera® (zanidatamab-hrii) in HER2-positive tumors, demonstrating significant efficacy in treating metastatic biliary tract cancer, thereby reinforcing its leadership in oncology.
- Clinical Trial Data: Data from the NeoZanHER trial will support the use of zanidatamab in early-stage HER2-positive breast cancer patients, which is expected to enhance the drug's clinical application in a broader range of HER2-expressing tumors, increasing the company's competitiveness in the oncology market.
- Innovative Research Initiatives: Jazz will also showcase studies on dordaviprone and JZP898, with the former showing potent cytotoxic effects in small cell lung cancer cell lines, while the latter demonstrates robust tumor microenvironment engagement in mouse models, indicating potential in tumor immunotherapy.
- Strategic Investments and Collaborations: The research findings not only reflect Jazz's ongoing investment in oncology drug development but also highlight the company's close collaboration with multiple partners, aiming to improve treatment options for patients through innovative therapies and further drive growth in the global biopharmaceutical market.
See More
